Research Article
Cost-Effectiveness of Anticoagulation in Patients with Nonvalvular Atrial Fibrillation with Edoxaban Compared to Warfarin in Germany
Table 4
Results of the base-case analysis for a 65-year-old population over a time horizon of 20 years from a German healthcare insurance perspective.
| Trial | Anticoagulant | QALY | Total costs
| ICER /QALY | Daily price /d | PSA ICER /QALY |
| ENGAGE-AF | Edoxaban 30 mg od | 7.65 | 21 052 | 68 275 | 3.37 | 69 600 | Warfarin | 7.48 | 9 747 | | 0.20 | | Edoxaban 60 mg od | 7.69 | 20 157 | 50 411 | 3.37 | 52 000 | Warfarin | 7.48 | 9 747 | | 0.20 | |
|
RE-LY [5] | Dabigatran 110 mg bid | 7.68 | 20 048 | 294 349 | 3.38 | 278 000 | Warfarin | 7.64 | 7 622 | | 0.20 | | Dabigatran 150 mg bid | 7.71 | 19 537 | 163 184 | 3.38 | 174 000 | Warfarin | 7.64 | 7 622 | | 0.20 | |
|
ROCKET-AF [5] | Rivaroxaban 20 mg od | 7.67 | 19 874 | 133 926 | 3.20 | 130 500 | Warfarin | 7.59 | 9 069 | | 0.20 | |
|
ARISTOTLE [5] | Apixaban 5 mg bid | 7.75 | 19 885 | 57 245 | 3.54 | 55 500 | Warfarin | 7.56 | 8 915 | | 0.20 | |
|
|